These Analysts Increase Their Forecasts On Boston Scientific After Upbeat Earnings

Core Insights - Boston Scientific Corporation reported third-quarter revenues of $5.07 billion, exceeding the consensus estimate of $4.97 billion, with adjusted earnings of 75 cents, surpassing both the consensus of 71 cents and management guidance of 70-72 cents [1] - The company forecasts net sales growth of approximately 20% in 2025 on a reported basis and around 15.5% on an organic basis, raising previous guidance of 18%-19% and 12%-14% respectively [2] - Adjusted earnings guidance was increased from $2.95-$2.99 to $3.02-$3.04, compared to the consensus of $2.98, with fourth-quarter adjusted earnings expected to be between 77 cents-79 cents versus consensus of 76 cents [2] Stock Performance - Following the earnings announcement, Boston Scientific shares gained 0.6% to trade at $104.40 [3] - Analysts have adjusted their price targets for Boston Scientific, with Morgan Stanley raising it from $125 to $130 and Wells Fargo from $124 to $125, both maintaining an Overweight rating [5]